Navigation

Multiple myeloma - bortezomib (induction therapy) [ID610]

Bortezomib for induction therapy prior to high dose chemotherapy and autologous stem cell transplantation for the treatment of multiple myeloma

Status: History
Expected date of issue: May 2014
Referral date: May 2012
Process: STA
Notes:

Scoped as part of Batch 22

Topic area:
 

NICE project team

Executive Lead: TBC
Technical Lead: Christian Griffiths
Communications manager: Alice Law
Project manager:

Nicole Fisher

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 04 Febuary 2013
1st appraisal committee meeting: 15 October 2013
2nd appraisal committee meeting 04 February 2014
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Janssen (bortezomib)

Patient/carer group

  • Myeloma UK
  • South Asian Health Foundation

Professional groups

  • British Society of Haematology
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • UK Myeloma Forum

Others

  • Department of Health
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency

Possible comparator manufacturers

Auden McKenzie (Pharma Division) (dexamethasone) (Confidentiality agreement not signed, not participating)

Baxter Healthcare (cyclophosphamide) (Confidentiality agreement not signed, not participating)

Celgene (thalidomide)

Hameln Pharmaceuticals (doxorubicin) (Confidentiality agreement not signed, not participating)

Hospira UK (doxorubicin) (Confidentiality agreement not signed, not participating)

Janssen (doxorubicin) (Confidentiality agreement not signed, not participating)

Medac UK (doxorubicin) (Confidentiality agreement not signed, not participating)

Merck Sharp & Dohme (dexamethasone) (Confidentiality agreement not signed, not participating)

Pfizer (cyclophosphamide, doxorubicin)

Rosemont Pharmaceuticals (dexamethasone) (Confidentiality agreement not signed, not participating)

Teva UK (doxorubicin) (Confidentiality agreement not signed, not participating)

Wockhardt UK (doxorubicin) (Confidentiality agreement not signed, not participating)

Relevant research groups

  • National Cancer Research Institute

Evidence Review Group

  • Southampton Health Technology Assessment Centre (SHTAC)
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
01 July 2013 To better align with the regulatory timings for this appraisal the 16 July Committee meeting has been cancelled.  The meeting has been rescheduled and will now take place on Tuesday 15 October 2013
30 January 2013 Due to a regulatory update from the manufacturer for this appraisal topic, the Committee discussion scheduled for Wednesday 15 May 2013 has been cancelled, this has been rescheduled for Tuesday 16 July 2013.
Top


 

Key documents

This page was last updated: 22 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.